G. Baciarello

718 total citations
18 papers, 440 citations indexed

About

G. Baciarello is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, G. Baciarello has authored 18 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in G. Baciarello's work include Prostate Cancer Treatment and Research (8 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Cancer Diagnosis and Treatment (6 papers). G. Baciarello is often cited by papers focused on Prostate Cancer Treatment and Research (8 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Cancer Diagnosis and Treatment (6 papers). G. Baciarello collaborates with scholars based in France, Italy and Switzerland. G. Baciarello's co-authors include Karim Fizazi, G. Soler, Lisa Derosa, Bernard Escudier, F. Losa Gaspà, Rafael Morales‐Barrera, Diégo Tosi, L. Chaigneau, Isabelle Borget and Aline Maillard and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

G. Baciarello

17 papers receiving 436 citations

Peers

Countries citing papers authored by G. Baciarello

Since Specialization

Citations

This map shows the geographic impact of G. Baciarello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Baciarello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Baciarello more than expected).

Fields of papers citing papers by G. Baciarello

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Baciarello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Baciarello. The network helps show where G. Baciarello may publish in the future.

Co-authorship network of co-authors of G. Baciarello

This figure shows the co-authorship network connecting the top 25 collaborators of G. Baciarello. A scholar is included among the top collaborators of G. Baciarello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Baciarello. G. Baciarello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	2368P Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial 2023 ·Annals of Oncology ·Patrizia Giannatempo, (unknown), Valentina Guadalupi, Laura Marandino, Daniele Raggi, Marco Stellato, (unknown), G. Baciarello, Pierangela Sepe, Mélanie Claps, Sebastiano Buti, Stefania Pipitone, Roberto Iacovelli, Giuseppina Calareso, Alessandra Alessi, Laura Cattaneo, Elena Verzoni, Cinzia Ortega, Giuseppe Procopio, Andrea Necchi	1
2	Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 2022 ·Annals of Oncology ·A. Krämer, Tilmann Bochtler, Chantal Pauli, G. Baciarello, Stefan Delorme, Kari Hemminki, Linda Mileshkin, Holger Moch, Karin A. Oien, Timothée Olivier, Anna Patrikidou, Harpreet Wasan, George Zarkavelis, George Pentheroudakis, Karim Fizazi	71
3	648P Abiraterone and dexamethasone in castration-resistant prostate cancer: Biological response after switch or rechallenge 2020 ·Annals of Oncology ·(unknown), (unknown), G. Baciarello, Clément Dumont, Clément Bonnet, Karim Fizazi, Stéphane Culine	0
4	638P Meningeal metastases (MM) in patients with metastatic castration resistant prostate cancer (mCRPC) 2020 ·Annals of Oncology ·Mihaela Aldea, Luigi Cerbone, (unknown), (unknown), Pernelle Lavaud, Alina Fuerea, Ronan Flippot, (unknown), Christophe Massard, Yohann Loriot, Laurence Albigès, G. Baciarello, Karim Fizazi	3
5	614MO Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects 2020 ·Annals of Oncology ·Mihaela Aldea, (unknown), (unknown), (unknown), Gwénaëlle Gravis, Aude Fléchon, Guilhem Roubaud, Philippe Barthélémy, Francesco Ricci, Franck Priou, (unknown), (unknown), Carole Hélissey, Raffaele Ratta, (unknown), (unknown), Antoine Thiery-Vuillemin, G. Baciarello, (unknown), Karim Fizazi	2
6	A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04) 2019 ·Annals of Oncology ·Karim Fizazi, Aline Maillard, Nicolas Penel, G. Baciarello, Djelila Allouache, Gedske Daugaard, A. van de Wouw, G. Soler, Élodie Vauléon, L. Chaigneau, René A. J. Janssen, F. Losa Gaspà, Rafael Morales‐Barrera, Carmen Balañá, Diégo Tosi, Bruno Chauffert, Claudia Schnabel, Géraldine Martineau, (unknown), Isabelle Borget	158
7	Comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients (pts) for targeted or immunotherapy treatment (tx) using the prospective CUPISCO trial’s criteria 2019 ·Annals of Oncology ·Jeffrey S. Ross, Ethan S. Sokol, Holger Moch, Linda Mileshkin, G. Baciarello, Ferrán Losa, Andreas Beringer, (unknown), Stefan Foser, Julia A. Elvin, Natalie Danziger, Nhu Ngo, (unknown), Keith Killian, Dongyun Jin, Laurie M. Gay, A. Krämer	4
8	A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience 2019 ·Annals of Oncology ·Chantal Pauli, Tilmann Bochtler, Linda Mileshkin, G. Baciarello, Ferrán Losa, Jeffrey S. Ross, G. Pentheroudakis, George Zarkavelis, Şuayib Yalçın, Mustafa Özgüroğlu, Andreas Beringer, Stefan Foser, (unknown), (unknown), Holger Moch, A. Krämer	3
9	Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients 2019 ·Annals of Oncology ·Valerio Iebba, Laurence Albigès, (unknown), Émeline Colomba, (unknown), Nicolas Pons, G. Baciarello, Emmanuelle Le Chatelier, Karim Fizazi, Bertrand Routy, Bernard Escudier, Laurence Zitvogel, Lisa Derosa	2
10	Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy 2018 ·Annals of Oncology ·A. Krämer, Ferrán Losa, Laurie M. Gay, Damian R. Page, Stefan Foser, Tariq I. Mughal, Jeffrey S. Ross, G. Baciarello, Linda Mileshkin, Stuart Osborne, Holger Moch	10
11	Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre 2018 ·European Journal of Cancer ·Fiorella Ruatta, Lisa Derosa, Bernard Escudier, Émeline Colomba, Annalisa Guida, G. Baciarello, Yohann Loriot, Karim Fizazi, Laurence Albigès	59
12	Patient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): Results from the CABADOC randomized trial 2017 ·Annals of Oncology ·Karim Fizazi, R. Delva, Gwénaëlle Gravis, G. Baciarello, Christine Théodore, Marine Gross‐Goupil, Emmanuelle Bompas, (unknown), Youssef Tazi, T. L'Haridon, (unknown), Philippe Barthélémy, Stéphane Culine, (unknown), (unknown), Philippe Beuzeboc, Aude Fléchon, (unknown), Géraldine Martineau, Isabelle Borget	1
13	Efficacy of cabozantinib (C) after PD-1/PD-L1 checkpoint inhibitors in metastatic renal cell carcinoma (mRCC): The Gustave Roussy experience 2017 ·Annals of Oncology ·Lisa Derosa, (unknown), Émeline Colomba, G. Baciarello, Bertrand Routy, Laurence Albigès, Bernard Escudier	10
14	Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL 2015 ·Annals of Oncology ·Julie N. Graff, G. Baciarello, Andrew J. Armstrong, (unknown), Pernille Iversen, Thomas W. Flaig, David Forer, Teresa Parli, D. Phung, Bertrand Tombal, Tomasz M. Beer, C. Sternberg	86
15	Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results. 2015 ·PubMed ·Federica Recine, Giovanni Luca Ceresoli, G. Baciarello, Luigi Cerbone, Fabio Calabrò	4
16	Early Psa Response is an Independent Prognostic Factor in Patients with Mcrpc Treated with Next-Generation Androgen Pathway Inhibitors 2014 ·Annals of Oncology ·Alina Fuerea, G. Baciarello, Christophe Massard, (unknown), (unknown), Safae Terrisse, Mario Di Palma, Bernard Escudier, Karim Fizazi, Yohann Loriot	3
17	Etoricoxib and anastrozole in adjuvant early breast cancer: ETAN trial (phase III). 2011 ·Journal of Clinical Oncology ·Maria Sofia Rosati, (unknown), G. Baciarello, Antonio Russo, Paolo Grassi, Luca Marchetti, (unknown), Marco Basile, L. Frati	6
18	Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I–II) 2010 ·Annals of Oncology ·Maria Sofia Rosati, Cristina Raimondi, G. Baciarello, Paolo Grassi, (unknown), (unknown), (unknown), Marco Girolami, (unknown), Luigi Frati	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact